Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-03-29
Based on 451 first isolates · GER · Febrile UTI / pyelonephritis · 2025-03-30 → 2026-03-29
Geriatrics
Per-organism detail: GER urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
meropenem 82 % (78 %–86 %)
Carbapenem: reserve for ESBL / critically ill patients.
Not covered: Enterococcus faecalis (11 %), Staphylococcus aureus (4 %), Staphylococcus saprophyticus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli not for this site
84 %
75 %
n = 28
meropenem MEM
trend · Escherichia coli reserve
82 %
89 %
n = 28
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
79 %
79 %
n = 28
mecillinam MEC
trend · Escherichia coli not for this site
76 %
75 %
n = 28
ceftriaxone CRO
trend · Escherichia coli
75 %
79 %
n = 28
ciprofloxacin CIP
trend · Escherichia coli
75 %
75 %
n = 28
71 %
79 %
n = 28
trimethoprim TMP
trend · Escherichia coli not for this site
68 %
64 %
n = 28
51 %
36 %
n = 28
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
11 %
n = 28
4 %
4 %
n = 28
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
4 %
n = 28

Most likely organisms for this profile

Escherichia coli
56 %
Enterococcus faecalis
11 %
Klebsiella pneumoniae
8 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
4 %
Staphylococcus aureus
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.